Nuclear medicine imaging is generally based on utilizing radioactive isotopes attached to specific molecules to examine biological processes, such as disease pathophysiology. These drugs can be administered orally, intravenously, or interstitially. Every radiopharmaceutical is designed to travel to a specific location in the body, and as soon as it reaches the site, it releases radioactive substances that kill the tumor cells. Radiopharmaceuticals can target various malignancies such as prostate cancer, heart disease, thyroid cancer, and others. These drugs can also be used as both therapies and diagnostics, known as 'theranostics. '
The "Global Radiopharmaceutical Theranostics Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of the radiopharmaceutical theranostics market with detailed market segmentation by radioisotope, source, approach, application, end user, and geography. The report provides key statistics on the market status of the leading radiopharmaceutical theranostics market players and offers key trends and opportunities in the market.
Based on radioisotope, the global radiopharmaceutical theranostics market is segmented into technetium-99, gallium-68, iodine-131, iodine-123, 18f, y-90, lutetium (lu) 177, copper (cu) 67, copper (cu) 64 and others.
On the basis of source, the market is bifurcated into nuclear reactors and cyclotrons.
On the basis of approach, the market is bifurcated into targeted therapeutic [Rx] and companion diagnostic [DX].
Based on application, the market is segmented into oncology, cardiology and others.
On the basis of end-users, the market is bifurcated into hospitals, academic & research institutes and others.
MARKET DYNAMICS Drivers:
Rise in the prevalence of cancer.
Increase in the availability of radioactive medicines by market players.
Rise in investments by key players for developing novel theranostics agents.
Rise in awareness of radiopharmaceuticals theranostics applications in disease treatment.
Stringent rules and regulations by the government.
Shortage of skilled professionals.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides an overview and forecast of the global market based on various segments. It also provides market size and forecast estimates from the year 2019 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), the Middle East and Africa (MEA), and South America. The radiopharmaceutical theranostics market by each region is later sub-segmented by respective countries and segments. The report covers the analysis and forecast of 18 countries globally along with the current trend and opportunities prevailing in the region.
The report analyzes factors affecting the market from both demand and supply side and further evaluates market dynamics affecting the market during the forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA, and South America after evaluating political, economic, social and technological factors affecting the radiopharmaceutical theranostics market in these regions.
IMPACT OF COVID-19ON RADIOPHARMACEUTICAL THERANOSTICS MARKET
COVID-19 first began in Wuhan (China) during December 2019, and since then, it has spread at a fast pace across the globe. The US, India, Brazil, Russia, France, UK, Turkey, Italy, and Spain are some of the worst affected countries in terms of confirmed cases and reported deaths. The COVID-19 pandemic has impacted the worldwide economy at various levels and has become a threat to global health. Due to the shutdown of manufacturing units, shortage in the supply of raw materials, and labor, there was a decline in the sales of market players. However, the radiopharmaceutical theranostics market stakeholders increased their R&D in nuclear medicine techniques, which was useful for functioning imaging of physiological processes at both cellular and molecular levels. Several advancements in radiolabeling methods also improved the radiopharmaceuticals accessibility for molecular imaging or radionuclide therapy, i.e., expected to surge the growth of the radiopharmaceutical theranostics market. Therefore, the pandemic has significantly affected the market's development and increased its growth.
Get more information on this report :
The report covers key developments in the radiopharmaceutical theranostics market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies activities witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for the expansion of business and customer base of market players. The market players from radiopharmaceutical theranostics market are anticipated to have lucrative growth opportunities in the future with the rising demand for radiopharmaceutical theranostics in the global market.
The report also includes the profiles of key companies along with their SWOT analysis and market strategies in the radiopharmaceutical theranostics market. In addition, the report focuses on leading industry players with information such as company profiles, components, and services offered, financial information of the last 3 years, the key development in the past five years.
ITM Isotopen Technologien München AG
Jubilant Pharma Limited
NuView Life Sciences
Lantheus Holdings, Inc.
Advanced Accelerator Applications
The Insight Partner's dedicated research and analysis team consist of experienced professionals with advanced statistical expertise and offer various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Nihon Medi-Physics
2. Clarity Pharmaceuticals
3. Telix Pharmaceuticals
4. GE Healthcare
5. Theragnostics Ltd
6. ITM Isotopen Technologien München AG
7. Jubilant Pharma Limited
8. NuView Life Sciences
9. Lantheus Holdings, Inc.
10. Advanced Accelerator Applications